Damora Therapeutics, Inc.
DMRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.47M
Close$
Share Statistics
| Market cap | $34.47 Million |
|---|---|
| Enterprise Value | $-506,044,834.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -50.93% |
|---|---|
| Return on Assets | -48.35% |
| Return on Invested Capital | -18.67% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 5.25 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Galecto Inc
28 employees
CEO: Jennifer A. Jarrett Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leadi...